Statement: The biggest change in Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4 observed in the primary trial was a patient in the AZD0530 175 mg group, with a -75.9 % change from baseline.
Primary_evidence: Outcome Measurement:    Percentage Change From Baseline in Serum Beta C-terminal Cross-linking Telopeptide of Type I Collagen (betaCTX) at Week 4   Result at Week 4 minus result at baseline as a percentage of the result at baseline, based on log transformed data. Back transformation of the least squares (LS) mean.   Time frame: Baseline to Week 4 Results 1:    Arm/Group Title: AZD0530 175 mg   Arm/Group Description: AZD0530 (saracatinib) 175 mg once daily   Overall Number of Participants Analyzed: 46   Geometric Mean (95% Confidence Interval)   Unit of Measure: Percentage change in betaCTX  -71.1        (-75.9 to -65.4) Results 2:    Arm/Group Title: Zoledronic Acid 4 mg   Arm/Group Description: Zoledronic Acid 4 mg on Day 1 of the 4-week treatment period   Overall Number of Participants Analyzed: 65   Geometric Mean (95% Confidence Interval)   Unit of Measure: Percentage change in betaCTX  -68.4        (-73.0 to -63.2)